News
University of North Florida and Humana Expand Meals on Wings Program to Address Food Insecurity Among Older Adults
The University of North Florida (UNF) and Humana Inc., a leading health and well-being company, have collaborated to expand the University’s Meals on Wings program into two new communities to help
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds the progressive expansion of coverage for continuous glucose
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds the progressive expansion of coverage for continuous glucose
Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now
Some income investors might view Pfizer (NYSE: PFE) stock as a falling knife to be avoided. After all, the big drugmaker's share price has already plunged more than 20% so far this year. Pfizer just
Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now
Some income investors might view Pfizer (NYSE: PFE) stock as a falling knife to be avoided. After all, the big drugmaker's share price has already plunged more than 20% so far this year. Pfizer just
7 Reasons to Buy Vertex Pharmaceuticals Stock Now
Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently
7 Reasons to Buy Vertex Pharmaceuticals Stock Now
Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently
7 Reasons to Buy Vertex Pharmaceuticals Stock Now
Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares